Tvardi Therapeutics (TVRD): Oppenheimer Sees Revenue Potential of $1.2 Billion and 138% Price Potential for the Stock!
Reading Time: 3 minutes
On May 14, Tvardi Therapeutics (TVRD) reported significant progress in the first quarter. The company successfully completed its merger with Cara Therapeutics. Through this transaction, the company received approximately $23.8 million in cash, in addition to a previously announced private financing round of $28.3 million in December 2024. These funds are expected to be sufficient to finance the company's activities until the second half of 2026, including key clinical milestones. Progress in the clinical development of TTI-101 Tvardi's main...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
